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Background. Conventional peritoneal dialysis fluids (PDF) have
been shown to compromise the function of both leukocytes and
human peritoneal mesothelial cells (HPMC). Various in vitro
studies have identified the low initial pH in combination with high
lactate content, as well as the hyperosmolality and high glucose
concentration present in currently used solutions as the primary
determinants of their bioincompatibility. Bicarbonate buffered
PDF (at neutral pH) display improved in vitro biocompatibility as
compared to conventional, lactate buffered PDF. However, little
information is currently available regarding the potential impact
of PDF on the function of human peritoneal fibroblasts (HPFB),
the major cell population present in peritoneal interstitium.
Methods. The current study compares the effect of bicarbonate
and lactate buffered PDF in a model system of resting peritoneal
mesothelial cells and fibroblasts cultured from human omentum.
Interleukin-1b-stimulated IL-6 release from HPMC and HPFB
was used as the cell functional parameter.
Results. While short (30 min) pre-exposure to lactate buffered
PDF significantly reduced the IL-1b-stimulated IL-6 release from
HPMC during a subsequent recovery period (24 hr), a significant
decrease in HPMC IL-6 secretion with bicarbonate buffered PDF
was only observed after prolonged ($60 min) exposure. In
contrast, no significant IL-6 inhibition was detected with HPFB
pre-exposed to PDF for up to 90 minutes. A significant suppres-
sion of HPFB IL-6 secretion was only observed in coincubation
experiments (24 hr) with dilutions of both types of PDF.
Conclusions. These results indicate that (i) bicarbonate buff-
ered PDF are less inhibitory to peritoneal cell function as
compared to conventional, lactate buffered PDF; and (ii) HPFB
may be more resistant than HPMC to bioincompatible PDF.
The peritoneal dialysis solution constitutes the primary
treatment/patient interface in chronic peritoneal dialysis, as
the peritoneal membrane of a patient undergoing continu-
ous ambulatory peritoneal dialysis (CAPD) is exposed to
approximately 3,000 liters per year of dialysis fluid. While
recent years have seen various improvements in systems
and techniques for fluid delivery and exchange, the com-
position of the solutions routinely used for peritoneal
dialysis has not changed during the past two decades,
despite the fact that their composition is unphysiological in
two repects: (1) lactate is employed as the standard buffer
system by which the pH of PDF is adjusted from pH 5.2 to
pH 5.5 in order to prevent glucose caramelization during
the industrial heat sterilization process; (2) glucose is
present in high concentrations as the osmotic agent result-
ing in a strong hyperosmolality of the PDF in order to
create an ultrafiltration gradient.
As a consequence, the repeated exposure of the perito-
neal membrane of PD patients to solutions with unphysio-
logical composition has raised questions as to the potential
acute and long-term biocompatibility of PDF.
The first in vitro biocompatibility studies of PDF date
back to 1981 when Duwe, Vas and Weatherhead reported
that both low pH and hyperosmolality of commercial
lactate-buffered PD fluids inhibit leukocyte functions such
as phagocytosis, bactericidal activity, and chemilumines-
cence [1]. Since then, a rapidly growing number of in vitro
studies with PD fluids has been published, virtually all of
which agree that the combination of lactate and acidic pH
adversely affect the function of both leukocytes and peri-
toneal mesothelial cells (Table 1) [reviewed in 21–23]. In
addition, few ex vivo studies in humans [24, 25] and in vivo
experiments using animal models [26–30] have further
supported the concept that conventional acidic PDF are
indeed bioincompatible.
Although the relevance of these findings in terms of
acute and long-term clinical consequences for the patients
undergoing CAPD remains to be established, the multitude
and severity of adverse effects that have been demonstrated
has impelled both clinical scientists as well as the manufac-
turers of dialysis fluids to explore and develop alternatives
for the currently used solutions. A primary focus in this
respect has been the development of solutions with neutral
pH as a first and seemingly logical approach to improve
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PDF biocompatibility. Bicarbonate, which constitutes a
major physiological buffer system in body fluids, had been
used for many years now as the gold standard in hemodi-
alysis. Now that the technical problems associated with its
use as the buffer system in peritoneal dialysis (such as,
necessity of two-chamber bags; stabilization of pH very
close to neutral range, that is, 7.4 6 0.2, to prevent
excessive PCO2) have been solved, several companies have
developed bicarbonate-buffered PDF, some of which are
currently undergoing clinical trials (Table 2). In addition,
some authors have proposed using histidine- [36] or pyru-
vate-buffered dialysis solutions [37–39]; however, these
proposals have not been widely tested in clinical trials thus
far.
Parallel to clinical safety and feasibility studies, the newly
formulated bicarbonate-buffered solutions are presently
undergoing a multifaceted approach to establish their
biocompatibility properties. In addition to the evaluation of
their impact on leukocyte functions, increasing attention is
focused on their effect on peritoneal membrane cells such
as mesothelial cells and fibroblasts. Both peritoneal me-
sothelial cells, constituting the superficial cell layer of the
peritoneal membrane, and peritoneal fibroblasts, constitut-
ing the major cell population of peritoneal interstitium,
possess a large biosynthetic repertoire for immunologically
active molecules including cytokines and prostaglandins
[40–49]. Consequently, their potentially important role in
peritoneal host defence appears to be established [50, 51].
While various investigations of the effect of (conventional
and alternative) PDF on mesothelial cells have been pub-
lished in recent years [19, 20, 52, 53], only scant information
is currently available regarding the effect of dialysis solu-
tions on peritoneal fibroblasts. The current study therefore
investigated the effect of bicarbonate- and lactate-buffered
PDF on cultured human peritoneal cells, thereby compar-
ing mesothelial cells and fibroblasts. The results of this
study suggest that, while bicarbonate buffered PDF are less
inhibitory to both peritoneal cell populations as compared
to conventional, lactate buffered PDF, the peritoneal fibro-
blasts appear to be less susceptible to PDF toxicity than the
peritoneal mesothelium.
METHODS
All chemicals were obtained from Sigma (Deisenhofen,
Germany) unless otherwise stated. Crude trypsin was from
Difco (Detroit, MI, USA). The culture vessels (25 cm2 and
75 cm2 culture flasks; 24-multiwell plates) were obtained
from Falcon Labware (Lincoln Park, NJ, USA). The dial-
ysis fluids (CAPD 2, CAPD 3, Bic 20 and Bic 30) were
obtained from Fresenius Medical Care (Bad Homburg,
Table 1. In vitro studies of pH/buffer effects on peritoneal dialysis fluids (PDF) biocompatibility
Author Cell type Cell functional parameter studied Reference
Duwe PBL chemiluminescence; phagocytosis; bacterial killing [1]
van Bronswijk PMØ, PMN chemiluminescence; phagocytosis; bacterial killing [2]
Topley PMØ, PMN chemiluminescence [3]
Alobaidi PMØ, PMN viability; phagocytosis [4]
Steinhauer PMØ TNFa, prostaglandin and leukotriene secretion [5]
Douvdevani PMØ TNFa mRNA expression; NF-kB DNA binding activity [6]
Douvdevani PMØ [pH]i; TNFa production; phagocytosis [7]
Douvdevani PMØ, PBMC TNFa and IL-1b secretion [8]
Jo¨rres PBMC TNFa and IL-6 secretion [9]
Jo¨rres PBMC, PMN TNFa and leukotriene release [10]
Jo¨rres PMN leukotriene release [11]
Gupta PMN (canine) superoxide production [12]
Ing PMN superoxide production [13]
Dobos PMN actin polymerisation; phagocytosis; chemotaxis [14]
Yu PMN [pH]i [15]
Liberek PMN [pH]i; respiratory burst activation [16]
Kaupke PMN [pH]i; adhesion; CD11b, CD18, and CD14 expression [17]
Moore LAK lytic activity in daudi cells [18]
van Bronswijk HPMC cytotoxicity (51Cr release); morphology [19]
Witowski HPMC IL-6 and PGE2 secretion [20]
Abbreviations are in the Appendix.
Table 2. Bicarbonate-buffered dialysis fluids undergoing clinical trials
Author Buffer composition Manufacturer Reference
Feriani Bicarbonate 34 mmol/liter Fresenius Medical Care [31,32]
Feriani Bicarbonate 39 mmol/liter Fresenius Medical Care [33]
Coles Bicarbonate 38 mmol/liter Baxter [34]
Coles Bicarbonate 25 mmol/liter 1 lactate 15 mmol/liter Baxter [34]
Yatzidis Bicarbonate 30 mmol/liter 1 glycylglycine 10 mmol/liter Pierre Fabre [35]
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Germany). The composition of these solutions is indicated
in Table 3.
Peritoneal cell culture
Human peritoneal mesothelial cells and fibroblasts were
cultured from human omentum essentially as described
previously [48, 54]. Briefly, the fibroblasts were cultured in
a humidified atmosphere, 5% CO2–95% air at 37°C, with
Ham’s F12 medium (ICN/Flow, Meckenheim, Germany),
the mesothelial cells in M 199 medium (ICN/Flow). Cul-
ture media were supplemented with penicillin (100 U/ml),
streptomycin (100 mg/ml), L-glutamine (2 mM), insulin (0.5
mg/ml), transferrin (0.5 mg/ml), hydrocortisone (0.4 mg/ml);
HEPES buffer (0.15 M; Gibco BRL, Berlin, Germany) and
10% vol/vol fetal calf serum (Gibco BRL). The pH was
adjusted from 7.3 to 7.4 by adding 1 M NaOH.
Human omental tissue was obtained from consenting
patients undergoing abdominal surgery. Omental speci-
mens were washed 33 in phosphate buffered saline (PBS;
Biochrom, Berlin, Germany) and pieces of approximately
10 cm2 were incubated in 15 ml trypsin/EDTA/glucose
(0.125%/0.01%/0.1 wt/vol in PBS) for 20 minutes at 37°C.
The suspension was centrifuged at 180 3 g and 4°C for five
minutes. The remaining tissue and trypsin/EDTA/glucose
solution were removed and the pelleted cells were washed
twice (180 3 g at 4°C for 5 min) in cell culture medium
containing 10% FCS to inhibit the trypsin activity. The
trypsin/EDTA digestion was repeated once for 20 minutes
followed by two more digestion steps of 40 minutes each.
The cells obtained during each disaggregation step were
resuspended in 5 ml cell culture medium and transferred to
25 cm2 culture flasks. The enzymatic disaggregation of
human omentum yielded homogeneous mesothelial cells
during the first incubation period and caused an increasing
release of fibroblasts during further trypsin/EDTA/glucose
treatment. From the third cycle HPFB were harvested
without contamination of mesothelial and other cells, as
assessed by phase contrast microscopy. Immunofluores-
cence staining of routine HPFB cultures characterized
these cells by their positive staining for vimentin and the
absence of staining for cytokeratin 18, factor VIII and
desmin while HPMC stained positive for for cytokeratin 18.
The primary cultures were incubated at 37°C, the me-
dium was exchanged after 24 hours for the first time and
every third day thereafter. Confluent cell cultures were
subcultured with trypsin/EDTA/glucose solution (0.125%/
0.01%/0.1%, wt/vol). The detachment of cells was observed
by light microscopy and the trypsin activity inhibited by
adding FCS supplemented culture medium thereafter. The
cells were washed twice in FCS supplemented culture
medium and seeded into new culture flasks at 1⁄3 of the
density of the previous culture.
For the incubation experiments HPFB and HPMC were
grown to confluence in 24-well plates and growth arrested in
cell culture medium with 0.1% FCS for 48 hours. Previous
experiments had established that under these culture condi-
tions both HPFB and HPMC remain in a viable, but nonpro-
liferative state for at least 72 hours [48, 54].
Incubation experiments with PDF
Confluent, nonproliferative HPFB monolayers were in-
cubated at 5% CO2 and 37°C for 15, 30, 45, 60, 75, and 90
minutes in the presence of test PDF, confluent nonprolif-
erative HPMC were exposed to PDF at 37°C for 15, 30, 45
and 60 minutes. Control measurements after up to 90
minutes preincubation showed that the pH of bicarbonate-
buffered fluids did not increase to above pH 7.6 under
these conditions. At the indicated time intervals the cell
supernatants were replaced by cell culture medium (0.1%
FCS) containing 100 pg/ml recombinant human interleu-
kin-1 beta (IL-1b) for 24 hours. Following this recovery/
stimulation period, cell supernatants were harvested, cen-
trifuged at 3000 3 g and stored at 220°C until further
analysis. Parallel dose-response experiments were run stim-
ulating HPFB with IL-1b for 24 hours in the presence of
PDF diluted [(vol/vol) (1:1) to (1:5)] with culture medium
containing 0.1% FCS. Incubation of HPFB or HPMC with
recombinant IL-1b (100 pg/ml) for up to 48 hours did not
affect cell viability or the levels of total cellular protein as
compared to cells treated with medium alone (data not
shown).
Enzyme immunoassay for interleukin-6
Interleukin-6 (IL-6) in cell supernatants was determined
as described previously [9]. Briefly, the enzyme immuno-
assay for IL-6 employed microtiter strips (Nunc, Wiesba-
den, Germany) coated with an affinity-purified polyclonal
rabbit anti-mouse IgG antibody (Dakopatts, Hamburg,
Germany) followed by a mouse monoclonal anti-human
IL-6 antibody (Serva, Heidelberg, Germany). IL-6 in sam-
ples and standards was detected by a sequence of incuba-
tions with: (i) a polyclonal anti-human IL-6 antibody
coupled to biotin (R&D Systems, Minneapolis, MN, USA);
(ii) horseradish peroxidase-streptavidin (Calbiochem,
Frankfurt, Germany); and (iii) tetramethyl benzidine sub-
strate buffer for color development (Fluka, Buchs, Switzer-
land). The IL-6 content of the samples was calculated from
Table 3. Composition of test solutions
CAPD 2 CAPD 3 Bic 20 Bic 30
Na1 mmol/liter 134 134 134 134
Cl2 mmol/liter 103.5 103.5 104.5 104.5
Ca21 mmol/liter 1.75 1.75 1.75 1.75
Mg21 mmol/liter 0.5 0.5 0.5 0.5
Lactate mmol/liter 35 35 — —
HCO3
2 mmol/liter — — 34 34
Glucose g/liter 15 42.5 15 42.5
pH 5.2–5.5 5.2–5.5 7.2–7.6 7.2–7.6
Osmolality mOsm/kg 358 511 358 511
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a standard curve using recombinant human IL-6 standards
(Janssen, Beerse, Belgium) ranging from 20 to 2,000 pg/ml.
The lower detection limit of the assay was 20 pg/ml. No
cross-reactivity with recombinant TNFa, TNFb, IL-1a,
IL-1b, IL-2, IL-3 or IL-4 was observed when these cyto-
kines were added to blank samples in concentrations up to
50 ng/ml (recombinant cytokines were obtained from Brit-
ish Biotechnology, Oxford, UK).
Statistical analysis
All statistical analyses were performed using the Wil-
coxon signed-ranks matched-pairs test for non-parametric
data. A two-sided P value of less than 0.05 was considered
as being significant. All data are presented as mean 6 SEM.
RESULTS
Interleukin-6 release from peritoneal fibroblasts pre-
exposed to dialysis fluids: Time course experiments
Control HPFB preincubated (15 to 90 min) in culture
medium released between 2588 6 235 pg/ml (mean 6 SEM;
at 30 min) and 3419 6 524 pg/ml IL-6 (at 90 min) following
stimulation (24 hr) with IL-1b (100 pg/ml). Neither with
cells pre-exposed for up to 90 minutes to lactate-buffered
acidic PDF (Fig. 1A), nor with cells incubated in bicarbon-
ate-buffered neutral PDF (Fig. 1B) was a significant reduc-
tion of IL-1b driven IL-6 secretion observed, irrespective of
the glucose concentration.
Fig. 1. Interleukin-6 release from peritoneal
fibroblasts preexposed for up to 90 minutes to
lactate-buffered, acidic PDF (A) or bicarbonate-
buffered, neutral PDF (B) followed by a 24-hour
recovery/stimulation period in the presence of
IL-1b (100 pg/ml). Symbols are: (in A) (M)
control; (p) lactate 1.5%; (s) lactate 4.25%;
(in B) (M) control; (o) bicarbonate 1.5%; (f)
bicarbonate 4.25%. Data are mean 6 SEM,
N 5 6 for lactate-buffered PDF and N 5 8 for
bicarbonate-buffered PDF.
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Interleukin-6 release from peritoneal mesothelial cells
pre-exposed to dialysis fluids: Time course experiments
Control HPMC preincubated (15 to 60 min) in culture
medium released (mean 6 SEM) between 1479 6 394 pg/ml
(at 45 min) and 1940 6 569 pg/ml IL-6 (at 60 min)
following subsequent of stimulation (24 hr) with IL-1b (100
pg/ml). With both low- and high-glucose containing lactate-
buffered PDF, a significant reduction of IL-1b driven IL-6
secretion from HPMC was observed following pre-expo-
sure periods of 30 minutes and longer (Fig. 2A). In
contrast, a significant IL-6 inhibition with low- and high
glucose containing bicarbonate-buffered PDF was evident
only after 60 minutes of preincubation (Fig. 2B). No
significant difference between the two glucose concentra-
tions could be detected with either buffer system.
Interleukin-6 release from peritoneal fibroblasts
coincubated in dialysis fluids: Dose response experiments
HPFB stimulated with IL-1b (100 pg/ml) for 24 hours in
the presence of low glucose-containing lactate-buffered
PDF showed a significant IL-6 suppression with dilutions of
1:1 and 1:2 (vol/vol), which was normalized with dilutions of
1:3 and above (Fig. 3A). With high glucose-containing
lactate-buffered PDF, a significant inhibition of HPFB IL-6
secretion was observed even in higher dilutions of 1:3 and
1:5 (Fig. 3B).
Fig. 2. Interleukin-6 release from peritoneal
mesothelial cells pre-exposed for up to 60
minutes to lactate-buffered acidic PDF (A) or
bicarbonate-buffered neutral PDF (B) followed
by a 24-hour recovery/stimulation period in the
presence of IL-1b (100 pg/ml). Symbols are:
(in A) (M) control; (p) lactate 1.5%; (s)
lactate 4.25%; (in B) (M) control; (o)
bicarbonate 1.5%; (f) bicarbonate 4.25%. Data
are mean 6 SEM, N 5 6 for both lactate-
buffered and bicarbonate-buffered PDF.
*Statistical significance (P , 0.05) versus
controls (cell culture medium) at the
corresponding time point.
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With low glucose-containing bicarbonate-buffered PDF,
a significant effect on IL-6 secretion was only evident in the
1:1 dilution, whereas cells exposed to dilutions of 1:2 and
higher showed a normal IL-6 response (Fig. 3C). Likewise,
with high glucose-containing bicarbonate-buffered PDF the
IL-6 inhibition was reversed with dilutions of 1:3 and above
(Fig. 3D).
DISCUSSION
Most previous biocompatibility studies of newly devel-
oped, neutral peritoneal dialysis fluids have employed
leukocytes that were acutely exposed in vitro to dialysis
fluids followed by the assessment of one or several cell
functional parameters. These static procedures, however,
do not resemble the in vivo situation of CAPD where a
dynamic process of fluid equilibration and peritoneal leu-
kocyte turnover is known to occur during the dialysis cycle.
As a consequence, cells are exposed in vivo to a very low pH
(,pH 6.0) only for few minutes, whereas some in vitro
studies used exposure periods of many hours, depending on
the test system employed. As an alternative, preincubation/
recovery systems have been developed in which the cells
were pre-exposed to test fluids only briefly, followed by a
recovery period in a balanced medium during (or at the end
of) which the cell functional parameters were assessed. For
both types of in vitro experiments, various leukocyte popu-
lations have been employed. Peritoneal macrophages
(PMØ) or polymorphonuclear leukocytes (PMN) were
harvested from the peritoneal effluent of CAPD patients.
While peritoneal leukocytes appear to be an obvious rele-
vant target for PDF biocompatibility studies, their use is
also associated with certain drawbacks. As a rule, the
number of cells available, at least in the effluent of non-
infected patients, is relatively low, resulting in certain limits
to the type, number and feasibility of in vitro experiments.
In addition, cells isolated from peritoneal effluent have
already been exposed to dialysis fluids in vivo that may
potentially influence the results of subsequent in vitro
experimentation. Alternatively, peripheral blood mononu-
clear cells (PBMC) and PMN isolated from the blood of
healthy donors or uremic patients have been studied. Since
these cells are the circulating precursors of PMØ and
Fig. 3. Interleukin-6 release from IL-1b-stimulated peritoneal fibroblasts coincubated with serial dilutions (vol/vol) of lactate-buffered (A, 1.5%
glucose, N 5 6; B, 4.25% glucose) or bicarbonate-buffered peritoneal dialysis fluids (C, 1.5% glucose, N 5 9; D, 4.25% glucose, N 5 7). *Statistical
significance (P , 0.05) versus controls (cell culture medium).
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peritoneal PMN they are generally accepted as valid test
systems for PDF biocompatibility studies. It has to be kept
in mind, however, that peripheral blood leukocytes may
differ from peritoneal cells with regard to the expression of
surface antigens and key mediator substances, including
cytokines and their antagonists, since these properties are
reportedly associated with the state of cell differentiation/
maturity [55]. Moreover, their sensitivity to the unphysio-
logical components of PDF such as pH or osmotic stress
may be different.
Finally, a wide range of parameters has been employed
to substantiate the potential impact of PDF on cell func-
tion, including cell respiration/respiratory burst/superoxide
production, phagocytosis and bacterial killing, intracellular
pH, intracellular ATP levels, cytokine mRNA expression
and secretion, and actin polymerization (Tables 1 and 4).
Despite this large variability outlined above regarding
cell populations, experimetal procedures and target param-
eters used for in vitro biocompatibility testing, virtually all
studies published to date agree that: (i) conventional,
lactate-buffered acidic PDF adversely affect in vitro leuko-
cyte function; and (ii) leukocyte function may be restored,
at least partially, by use of alternative neutral PDF irre-
spective of the buffer system used (Table 4). This view is
further supported by emerging ex vivo studies in CAPD
patients indicating that in vivo exposure of PMØ to bicar-
bonate/lactate-buffered PDF or bicarbonate-buffered PDF
improves their subsequent ability to secrete TNFa [71].
More recently, research interest has focused on the effect
of PDF on resident peritoneal membrane cells such as
mesothelial cells and fibroblasts, since their repeated expo-
sure to bioincompatible solutions might, at least theoreti-
cally, impact on the long-term function of the peritoneal
membrane as a dialyzing organ. Earlier work by Witowski
et al indicated that a short (15 to 30 min) pre-exposure of
HPMC to lactate-buffered acidic PDF resulted in a signif-
icant inhibition of their IL-1b driven IL-6 secretion, which
was reversed when the solution was neutralized [20]. Using
a similar experimental setup, Topley et al recently showed
that both bicarbonate-buffered [53] or bicarbonate/lactate-
buffered [52] neutral solutions did not significantly inter-
fere with HPMC intracellular ATP levels or IL-1b driven
IL-6 secretion, both of which were significantly reduced by
conventional acidic PDF.
In contrast to these emerging data on the effect of
alternative neutralized PDF on peritoneal mesothelial
cells, virtually no information has been available to date
regarding the potential impact of these fluids on peritoneal
fibroblast function. Since HPFB not only constitute the
major cell population of peritoneal interstitium, but also
were shown to be substantially involved in the peritoneal
cytokine network regulating peritoneal inflammation [47–
49], the current study investigated the effect of alternative,
neutral PDF versus conventional, acidic PDF, on perito-
neal fibroblasts compared to peritoneal mesothelial cells,
using an in vitro experimental setup that has been previ-
ously established for the evaluation of PDF effects on
HPMC function [52, 53].
Short (30 min) pre-exposure to lactate-buffered PDF
significantly reduced the IL-1b-stimulated IL-6 release
from HPMC during a subsequent recovery period (24 hr) in
culture medium, while exposure to bicarbonate-buffered,
neutral PDF resulted in a significant inhibition of HPMC
IL-6 secretion only after a prolonged ($60 min) exposure.
In contrast, neither lactate-buffered acidic PDF nor bicar-
bonate-buffered neutral PDF significantly affected IL-1b-
stimulated IL-6 secretion irrespective of the glucose con-
centration when HPFB were pre-exposed for up to 90
Table 4. In vitro biocompatibility studies of peritoneal dialysis fluids (PDF) with alternative buffers
Author Cell type Cell functional parameter studied Reference
Jo¨rres PBMC TNFa and IL-6 mRNA expression and secretion [56]
Jo¨rres PBMC TNFa and IL-6 mRNA expression and secretion [57]
Plum PBMC LDH release; MTT test; IL-1b and IL-6 secretion [58]
Mahiout PBMC, PMØ TNFa mRNA expression; chemotaxis; superoxide production [38]
Mahiout PMØ cytokine synthesis; superoxide production [39]
Fischer PMØ chemiluminescence; phagocytosis; bacterial killing [59]
Schambye PMN migration; phagocytosis [60]
Topley PMN leukotriene B4 secretion; phagocytosis [36]
Ing PMN superoxide production [61]
Manahan PMN superoxide production [62]
Dobos PMN cytosolic Ca21 mobilisation; superoxide production [63]
Schambye PMN migration [64]
Sundaram PMN, PBMC TNFa and BPI release; phagocytosis; oxidative burst [65]
Topley PMN, HPMC ATP levels; phagocytosis; respiratory burst; IL-6 release [53]
Topley PMN; HPMC ATP levels; phagocytosis; respiratory burst; IL-6 release [52]
Dobos PMN actin polymerisation; phagocytosis; chemotaxis [66]
Fougeray HPMC cell proliferation [67]
Brunkhorst HPMC viability; proliferation [37]
Kristensen L929 ATP levels; LDH release [68]
Buonchristiani RBC glycolysis (Embden-Meyerhoff pathway) [69]
Rogachev PMØ [pH]i; TNFa mRNA expression and secretion [70]
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minutes to these solutions, suggesting that HPFB may be
more resistant than HPMC to the unphysiological proper-
ties of peritoneal dialysis solutions. Additional coincuba-
tion, dose-response experiments with dilutions of lactate or
bicarbonate buffered PDF indicated, however, that pro-
longed exposure to dialysis fluids may lead to an inhibition
of HPFB IL-6 secretion in a dose-dependent fashion. In
this coincubation system the high glucose-containing PDF
showed stronger effects than their low glucose counter-
parts, and the bicarbonate buffered solutions were gener-
ally less inhibitory as compared to the lactate buffered PDF
when tested at the same dilution. This finding is of partic-
ular interest, since in higher dilutions the pH of the lactate
buffered PDF was neutralized by the addition of cell
culture medium. Thus, the differences outlined above
cannot only be explained by the different acidity, glucose
content and hyperosmolality of the solution. Thus, a hypo-
thetical explanation may be the lesser presence in bicar-
bonate buffered fluids of additional potentially toxic factors
such as glucose degradation products (GDP) [72–75]. Since
the amount of GDP produced during heat sterilization of
glucose solutions is dependent not only on the glucose
concentration but also on the pH at which the sterilization
process takes place, their concentration is significantly
lower in bicarbonate buffered solutions where the glucose
is contained in a separate compartment at a very low pH
[76, 77], whereas conventional PDF regularly contain high
GDP concentrations [78].
Taken together, the results of the current study add
further evidence to support the notion that bicarbonate-
buffered, neutral peritoneal dialysis fluids offer improved
biocompatibility properties as compared to conventional,
acidic lactate-buffered solutions. The issue of whether the
type of buffer per se influences cell function remains less
well characterized. Overall, it appears that bicarbonate
buffered fluids improve cell function irrespective of their
composition (such as, bicarbonate alone, bicarbonate/lac-
tate, or bicarbonate/glycylglycine); however, a few studies
also indicate that, particularly in the presence of high
glucose concentrations, bicarbonate buffered solutions may
preserve cell function better than an otherwise identical,
pH neutral lactate-buffered solution [53, 59]. This area
quite clearly requires further investigation.
The general question that remains to be answered is the
issue of the potential biological relevance of the improved
in vitro biocompatibility of the neutral dialysis solutions. In
terms of acute effects this would culminate in the question
of whether the improved phagocyte, HPMC and HPFB
function will, for example, lead to a reduction of peritonitis
rates, or, alternatively, if the incidence of infectious com-
plications will be increased due to an improved survival of
microorganisms in biocompatible fluids. The clinical stud-
ies performed thus far or that are currently underway do
not systematically address this question. However, as far as
initial observations go, a major difference in peritonitis
rates between alternative and conventional solutions has
not yet been observed [31–35]. An important issue regard-
ing long-term outcome will be the potential impact of the
dialysis fluids on the incidence of peritoneal sclerosing
syndromes and ultrafiltration failure. Quite clearly, answers
to these questions can only be provided by controlled,
randomized and prospective clinical trials of alternative
versus conventional solutions. Such trials will, however,
require a large number of patients studied longitudinally
for several years before final conclusive results will be
available. In addition, it should not be forgotten that
avoiding PDF acidity may help to resolve only part of the
PDF bioincompatibility problem since an optimal osmotic
agent, both avoiding the metabolic effects as well as the
potential cytotoxicity of high glucose concentrations, is not
yet available. The achievement of physiological pH, how-
ever, constitutes a realistic short-term goal that appears to
be well substantiated by the evidence published to date,
and, at least in the case of solutions manufactured in
two-compartment bags, may at the same time minimize the
potential problems associated with glucose degradation
products. It is thus to be expected that as soon as they are
available on a regular basis, and provided that their use is
also economically viable, the neutral PD fluids with alter-
native buffer systems will be utilized widely even before
conclusive clinical data are available.
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APPENDIX
Abbreviations used in this article are: ATP, adenosine
59-triphosphate; BPI, bactericidal/permeability increasing
protein; CAPD, continuous ambulatory peritoneal dialysis;
HPFB, human peritoneal fibroblasts; HPMC, human peri-
toneal mesothelial cells; IL, interleukin; LAK, lymphokine-
activated killer cells; LDH, lactate dehydrogenase; NF-kB,
nuclear factor-kB; PBL, peripheral blood leukocytes;
PBMC, peripheral blood mononuclear leukocytes; PDF,
peritoneal dialysis fluid; PG, prostaglandin; [pH]i, intracel-
lular pH; PMN, polymorphonuclear leukocytes; PMØ,
peritoneal macrophages; TNFa, tumor necrosis factor
alpha.
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